

# **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

## **MedX Holdings, Inc.**

A Wyoming Corporation

1621 Central Avenue  
Cheyenne, WY 82001

---

(737) 777-0420

www.medxholdings.co

hans@dazedinc.com

6552

### **Annual Report**

**For the Period Ending: December 31, 2020**  
(the "Reporting Period")

As of 12/31/2020, the number of shares outstanding of our Common Stock was: 143,499,016

As of 09/30/2020, the number of shares outstanding of our Common Stock was: 123,499,016

As of 12/31/2019, the number of shares outstanding of our Common Stock was: 53,499,016

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒ (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes: ☐

No: ☒

<sup>A</sup> See Subsequent Events

<sup>1</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

MedX Holdings, Inc. as of 12/15/2015

Cantor Group Inc. as of 08/12/2015

Disaboom, Inc. as of 11/12/2006

Disaboo, Inc. as of 09/05/2006

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The Company was incorporated on September 5, 2006 as Disaboo, Inc. under the laws of the state of Colorado.

The Company was redomiciled to the State of Wyoming on December 28, 2015.

The Company's status is Active in the state of Wyoming.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

MedX Holdings, Inc. 1621 Central Avenue

Cheyenne, WY 82001

The address(es) of the issuer's principal place of business:

*Check box if principal executive office and principal place of business are the same address:* ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐

No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

None

## 2) Security Information

Trading symbol:	<u>MEDH</u>		
Exact title and class of securities outstanding:	<u>Common Stock</u>		
CUSIP:	<u>58403T 107</u>		
Par or stated value:	<u>\$0.001</u>		
Total shares authorized:	<u>1,000,000,000</u>	as of date:	<u>12/31/2019</u>
Total shares outstanding:	<u>143,499,016</u>	as of date:	<u>12/31/2020</u>
Number of shares in the Public Float <sup>5</sup> :	<u>118,724,016</u>	as of date:	<u>12/31/2020</u>
Total number of shareholders of record:	<u>237</u>	as of date:	<u>12/31/2020</u>

*All additional class(es) of publicly traded securities (if any):*

Trading symbol:	<u>MEDH</u>		
Exact title and class of securities outstanding:	<u>Preferred</u>		
Par or stated value:	<u>Stock .001</u>		
Total shares authorized:	<u>100,000,000</u>	as of date:	<u>12/31/2019</u>
Total shares outstanding PreferredA:	<u>2,900,000</u>	as of date:	<u>12/31/2020</u>
Total shares outstanding PreferredB:	<u>4,000,000</u>	as of date:	<u>12/31/2020</u>
Total shares outstanding PreferredC:	<u>50,000</u>	as of date:	<u>12/31/2020</u>

### Transfer Agent

Name: EQ Shareowner Services  
Phone: 303-282-4800  
Email: karen.naughton@Equiniti.com

Is the Transfer Agent registered under the Exchange Act?<sup>6</sup> Yes: ☒ No: ☐

<sup>5</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>6</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.  
OTC Markets Group Inc.  
OTC Pink Basic Disclosure Guidelines (v3 February 2021)

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>01/01/2017</u> Common: <u>39,694,016</u> Preferred-A: <u>400,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>03/31/17</u>	<u>New Issuance</u>	<u>72,917,200</u>	<u>Common</u>	<u>.0025</u>	<u>Yes</u>	<u>Kathleen Robertson</u>	<u>Salary and Expenses</u>	<u>Restricted</u>	<u>4(2)</u>
<u>01/15/18</u>	<u>New Issuance</u>	<u>4,000,000</u>	<u>Preferred B</u>	<u>.25</u>	<u>No</u>	<u>Mark Miller</u>	<u>Acquisition</u>	<u>Restricted</u>	<u>4(2)</u>
<u>03/10/18</u>	<u>Transfer</u>	<u>98,117,200</u>	<u>Common</u>	<u>.0025</u>	<u>No</u>	<u>Mark Miller</u>	<u>Control Block</u>	<u>Restricted</u>	<u>4(2)</u>
<u>04/19/18</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>.0003</u>	<u>Yes</u>	<u>PAG Group Gary Kouletas</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>144</u>
<u>12/04/18</u>	<u>New Issuance</u>	<u>11,000,000</u>	<u>Common</u>	<u>.0003</u>	<u>Yes</u>	<u>PAG Group Gary Kouletas</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>144</u>

<u>06/02/19</u>	<u>New Issuance</u>	<u>13,000,000</u>	<u>Common</u>	<u>.0002</u>	<u>Yes</u>	<u>Saied Jaberian</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>144</u>
<u>10/02/19</u>	<u>Canceled</u>	<u>295,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Mark Miller</u>	<u>Canceled</u>	<u>Restricted</u>	<u>N/A</u>
<u>11/26/19</u>	<u>New Issuance</u>	<u>2,500,000</u>	<u>Preferred A</u>	<u>.001</u>	<u>No</u>	<u>Mark Miller</u>	<u>Salary</u>	<u>Restricted</u>	<u>4(2)</u>
<u>12/12/19</u>	<u>Canceled</u>	<u>93,117,200</u>	<u>Common</u>	<u>.0025</u>	<u>No</u>	<u>Mark Miller</u>	<u>Canceled</u>	<u>Restricted</u>	<u>4(2)</u>
<u>12/20/19</u>	<u>New Issuance</u>	<u>50,000</u>	<u>Preferred C</u>	<u>.01</u>	<u>No</u>	<u>Jason Black</u>	<u>Control Block</u>	<u>Restricted</u>	<u>4(2)</u>
<u>1/1/20</u>	<u>Canceled</u>	<u>4,000,000</u>	<u>Preferred B</u>	<u>.25</u>	<u>No</u>	<u>Mark Miller</u>	<u>Canceled</u>	<u>Restricted</u>	<u>4(2)</u>
<u>2/24/20</u>	<u>New Issuance</u>	<u>4,000,000</u>	<u>Preferred B</u>	<u>.25</u>	<u>No</u>	<u>Bio Hydro LLC Jeremy Amsden</u>	<u>Acquisition</u>	<u>Restricted</u>	<u>4(2)</u>
<u>6/30/20</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>.001</u>	<u>Yes</u>	<u>Capitol Capital Corp Howard Salamon</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>144</u>
<u>07/01/20</u>	<u>New Issuance</u>	<u>60,000,000</u>	<u>Common</u>	<u>.001</u>	<u>Yes</u>	<u>PAG Group Gary Kouletas</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>144</u>
<u>07/27/20</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>.001</u>	<u>Yes</u>	<u>Capitol Capital Corp Howard Salamon</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>144</u>
<u>11/29/20</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>.0001</u>	<u>Yes</u>	<u>Northwoods Elite LLC Richard Kilchesky</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>144</u>
<u>12/17/20</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>.0001</u>	<u>Yes</u>	<u>Northwoods Elite LLC Richard Kilchesky</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>144</u>
Shares Outstanding on Date of This Report <u>Ending Balance:</u>									
Date <u>12/31/20</u> Common: <u>143,499,016</u>									
Preferred-A: <u>2,900,000</u>									
Preferred-B: <u>4,000,000</u>									
Preferred-C: <u>50,000</u>									

Use the space below to provide any additional details, including footnotes to the table above:

On December 20, 2019 the Company issued 50,000 Preferred C super voting shares to Jason Black, resulting in a change of control, whereby the Company accepted the resignation of Mark Miller as a Director or officer of the Company, leaving Jason Black as sole Director of the Company and interim President.

On February 24, 2020 the Company completed the acquisition of Bio Hydro LLC through the issuance of 4,000,000 Preferred B shares.

On June 5, 2020 Jeremy Amsden resigned as CEO and Hans Enriquez was appointed as CEO.

On July 1, 2020 the Company issued 60,000,000 shares to PAG Group for consulting fees.

On November 29, 2020 Northwoods Elite converted 10,000,000 shares from a convertible note.

On December 17, 2020 Northwoods elite converted 10,000,000 shares from a convertible note.

## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities..

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
<u>10/22/19</u>	<u>\$21,242</u>	<u>\$18,500</u>	<u>\$2,742</u>	<u>10/23/20</u>	<u>.0001</u>	<u>Northwoods Elite</u> <u>Richard Kilchesky</u>	<u>Loan</u>
<u>12/20/19</u>	<u>\$75,000</u>	<u>\$70,000</u>	<u>\$5000</u>	<u>12/19/20</u>	<u>.001</u> <u>Debt Settlement -</u> <u>Not to exceed \$75,000</u>	<u>Mark Miller</u>	<u>Purchase of</u> <u>Control Block</u>

Use the space below to provide any additional details, including footnotes to the table above:

On December 20, 2019 the Company issued a \$70,000 convertible note to Mark Miller for the purchase of the Preferred C control block.

On November 17, 2020 the Company entered into a debt settlement agreement with Mark Miller to cap the convertible note debt at \$75,000.

## 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP  
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>4</sup>:

Name: Hans Enriquez  
Title: CFO  
Relationship to Issuer: CEO

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Changes in Shareholders' Equity
- G. Financial notes;

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below.

The Company's financial statements are incorporated herein.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

## **5) Issuer's Business, Products and Services**

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Commercial Real Estate Development

- B. Please list any subsidiaries, parents, or affiliated companies

The Company operates through its subsidiary Bio Hydro LLC which is focused on developing pharmaceutical grade water assets in the Maricopa County, Arizona saturated zone.

- C. Describe the issuers' principal products or services.

Commercial Real Estate Development

---

<sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

## 6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company operates through its subsidiary Bio Hydro LLC which is focused on developing pharmaceutical grade water assets in the Maricopa County, Arizona saturated zone.

The company has identified a land lease target that it intends to acquire. To date, the lease has not been executed.

Corporate Office: MedX Holdings, Inc. 1621 Central Avenue  
Cheyenne, WY 82001

## 7) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information regarding any person or entity owning 5% or more of the issuer, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**



Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Jason Black</u>	<u>Owner of more than 5%</u>	<u>Marietta, GA</u>	<u>50,000</u>	<u>Preferred C</u>	<u>100%</u>	<u>      </u>
<u>Hans Enriquez</u>	<u>Director/CEO/CFO</u>	<u>Austin, TX</u>	<u>None</u>	<u>N/A</u>	<u>N/A</u>	<u>Appointed 06/05/20</u>

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

NONE

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

NONE

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

NONE

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NONE

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

## 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

### Securities Counsel

Name: Jonathan Leinwand, Esq.  
Firm:  
Address 1: 20900 NE 30th Ave. 8<sup>th</sup> Floor  
Address 2: Aventura, FL 33180  
Phone: (954) 903-7856  
Email: jonathan@jdlpa.com

Accountant or Auditor

Name:  
Firm:  
Address 1:  
Address 2:  
Phone:  
Email:

Investor Relations Consultant

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Other Service Providers

Provide the name of any other service provider(s), including, counsel, advisor(s) or consultant(s) **that assisted, advised, prepared or provided information with respect to this disclosure statement**, or provided assistance or services to the issuer during the reporting period.

Name: Erwin Vahlsing, Jr.  
Firm: XBRL Associates, Inc.  
Nature of Services: Consult on Financials and Disclosures  
Address 1: PO Box 19652  
Address 2: Johnston, RI 02919  
Phone: (401) 648-0802  
Email: evahlsing@xbrlassociates.com

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Hans Enriquez certify that:

1. I have reviewed this Annual Disclosure Statement of MedX Holdings, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

03/05/2021

/s/ Hans Enriquez [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

### *Principal Financial Officer:*

I, Hans Enriquez certify that:

1. I have reviewed this Annual Disclosure Statement of MedX Holdings, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

03/05/2021

/s/ Hans Enriquez [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

**MEDX HOLDINGS, INC.  
(MEDH)**

**QUARTERLY REPORT  
FOR THE YEAR ENDING DECEMBER 31, 2020**

March 5, 2021

1621 Central Avenue  
Cheyenne  
WY 82001

**MEDX HOLDINGS, INC.**  
**QUARTERLY REPORT**  
**FOR THE YEAR ENDING DECEMBER 31, 2020**  
**(Unaudited)**

**Index**

Condensed Consolidated Unaudited Financial Statements	3
Condensed Consolidated Unaudited Balance Sheet as at December 31, 2020 and December 31, 2019	3
Condensed Consolidated Unaudited Statement of Operations for Year Ending December 31, 2020 and 2019	4
Condensed Consolidated Unaudited Statement of Cash Flow for Year Ending December 31, 2020 and 2019	5
Condensed Unaudited Statement of Changes in Equity for the Year Ending December 31, 2020 and December 31, 2019	6
Notes the Condensed Consolidated Unaudited Financial Statements	7

**MEDX HOLDINGS, INC.**  
**Condensed Consolidated Unaudited Financial Statements**  
**Balance Sheet**

	Notes	As at December 31, 2020	As at December 31, 2019
<b>ASSETS</b>			
Current assets			
Cash and cash equivalents	2	\$ -	\$ 2,450,051
Accounts receivable	2	-	-
Other current assets	5	-	-
Total current assets		-	2,450,051
Fixed and intangible assets			
Equipment	6	37,500	37,500
Accumulated depreciation and amortization	6	(22,500)	(15,000)
Intangible assets	7	200	200
Goodwill	7	996,000	-
Capitalized re-organization costs	7	-	-
TOTAL ASSETS		<u>\$ 1,011,200</u>	<u>\$ 2,472,751</u>
<b>LIABILITIES &amp; STOCKHOLDERS' EQUITY (DEFICIT)</b>			
Current liabilities			
Accounts payable, trade		\$ -	\$ -
Accrued expenses and other current liabilities		-	15,574
Short-term or current loans and notes payable, net of debt discount of nil	8	96,242	5,271
Derivative liability	9	769,936	576,573
Total current liabilities		866,178	597,418
Long-term loans and notes payable	8	-	-
TOTAL LIABILITIES		<u>\$ 866,178</u>	<u>\$ 597,418</u>
<b>STOCKHOLDERS' EQUITY (DEFICIT)</b>			
Preferred stock:			
Preferred stock series A: par value \$0.001, 50,000,000 authorized and 2,900,000 issued and outstanding at December 31, 2020 and December 31, 2019	10	2,900	2,900
Preferred stock series B: par value \$0.001, 40,000,000 authorized and 4,000,000 issued and outstanding at December 31, 2020 and December 31, 2019	10	4,000	4,000
Preferred stock series C: par value \$0.01, 10,000,000 authorized and 50,000 issued and outstanding at December 31, 2020 and December 31, 2019	10	500	500
Common stock: par value \$0.001, 1,000,000,000 and 200,000,000 authorized and 143,499,016 and 53,499,016 issued and outstanding as at December 31, 2020 and December 31, 2019 respectively	10	102,699	40,199
Additional paid-in capital		2,236,284	2,236,284
Accumulated surplus (deficit)		(2,201,361)	(408,550)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)		145,022	1,875,333
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		<u>\$ 1,011,200</u>	<u>\$ 2,472,751</u>

See accompanying notes to these condensed consolidated unaudited financial statements.

**MEDX HOLDINGS, INC.**  
**Condensed Consolidated Unaudited Financial Statements**  
**Statement of Operations**

	Year Ending December 31,	
	2020	2019
Revenues	\$ -	\$ 1,480,732
Cost of goods sold	-	647,169
Gross profit	-	833,563
Operating expenses		
Selling, general & admin. costs	54,487	513,577
Depreciation and amortization	7,500	12,104
Total operating expenses	61,987	525,681
Income (loss) from operations	(61,987)	307,882
Other income (expenses)		
Financing costs	(9,766)	(1,784)
Amortization of debt discount	(95,500)	77,780
Gain (loss) on change in value of derivative	(190,363)	(531,605)
Preferred stock series A beneficial conversion	-	(635,273)
Other income (expenses)	(2,379,990)	(27,251)
Income (loss) before income taxes	\$ (2,737,606)	\$ (810,250)
Provision for income taxes	-	-
Net income (loss)	\$ (2,737,606)	\$ (810,250)
Net income (loss) per share	\$ (0.03)	\$ (0.01)
Weighted average shares outstanding	98,499,016	93,555,116

See accompanying notes to these condensed consolidated unaudited financial statements.

**MEDX HOLDINGS, INC.**  
**Condensed Consolidated Unaudited Financial Statements**  
**Statement of Cash Flow**

	Year Ending December 31,	
	2020	2019
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net income (loss)	\$ (2,737,606)	\$ (810,250)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization	7,500	12,104
Stock issued for acquisitions	-	2,500
Amortization of debt discount	95,500	(73,401)
Change in fair value of derivative liability	190,363	531,605
Preferred stock series A beneficial conversion feature	-	635,273
Financing costs	9,766	1,784
Changes in operating assets and liabilities:		
Accounts receivable	-	48,120
Accounts payable and other current liabilities	(15,574)	12,355
Other current assets	-	772,773
<b>NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</b>	<b>(2,450,051)</b>	<b>1,132,863</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
(Purchase) sale of property	-	385,700
(Purchase) sale of intangible assets	-	1,000,000
Investment in short-term loans	-	-
<b>NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</b>	<b>-</b>	<b>1,385,700</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issuance of equity (dividend distributions)	2,000	500
Proceeds from (repayment of) debt instruments	7,766	(285,616)
Short-term line of credit	-	-
Payment of related-party debt	-	-
Financing costs	(9,766)	(1,784)
<b>NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</b>	<b>-</b>	<b>(286,900)</b>
<b>EXCHANGE RATE MOVEMENTS</b>	<b>-</b>	<b>-</b>
<b>NET INCREASE (DECREASE) IN CASH</b>	<b>(2,450,051)</b>	<b>2,231,663</b>
Cash, beginning of period	2,450,051	218,388
Cash, end of period	\$ -	\$ 2,450,051
<b>SUPPLEMENTAL DISCLOSURES</b>		
<u>Supplemental schedule of cash flow information:</u>		
Interest paid	\$ -	\$ -
Income taxes paid	\$ -	\$ -
<u>Supplemental schedules of non-cash investing and financing activities:</u>		
Preferred stock issued for services and acquisition of subsidiaries, respectively	\$ 4,000	\$ 2,500
Common stock canceled/issued for services, respectively	\$ -	\$ 14,271
Conversion of debt to common stock	\$ 8,030	\$ -

See accompanying notes to these condensed consolidated unaudited financial statements.



**MEDX HOLDINGS, INC.**  
**Condensed Consolidated Unaudited Financial Statements**  
**Statement of Changes in Stockholders' Equity**

	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance b/f as at January 1, 2019	\$ 4,400	\$ 133,611	\$ 1,601,011	\$ 401,700	\$ 2,140,722
Common stock cancelled and returned	-	(93,412)	-	-	(93,412)
Preferred stock Series A issued	2,500	-	635,273	-	637,773
Preferred stock Series C issued	500	-	-	-	500
Net loss for year ended December 31, 2019	-	-	-	(810,250)	(810,250)
Balance b/f as at January 1, 2020	\$ 7,400	\$ 40,199	\$ 2,236,284	\$ (408,550)	\$ 1,875,333
Preferred stock Series B canceled on divestment	(4,000)	-	-	4,000	-
Preferred stock Series B issued for acquisition	4,000	-	-	996,000	1,000,000
Common stock issued in part repayment of debt	-	62,500	-	(55,205)	7,295
Net income for year ended December 31, 2020	-	-	-	(2,737,606)	(2,737,606)
Balance c/f as at December 31, 2020	<u>\$ 7,400</u>	<u>\$ 102,699</u>	<u>\$ 2,236,284</u>	<u>\$ (2,201,361)</u>	<u>\$ 145,022</u>

See accompanying notes to these condensed consolidated unaudited financial statements.

**MEDX HOLDINGS, INC.**  
**Condensed Consolidated Unaudited Financial Statements**  
**Notes For the Year Ending December 31, 2020**

**NOTE 1. NATURE AND BACKGROUND OF BUSINESS**

The accompanying consolidated financial statements include MEDX Holdings, Inc., its wholly-owned subsidiaries and any majority controlling interests.

Originally a development business, the Company has now become a holding company focused on acquiring businesses throughout the United States which have proven track records to maximize return on investment. Through its subsidiaries, the Company acquires real estate and develops and builds residential and commercial properties for immediate sale or long-term cash flow.

The Company was originally incorporated in Colorado on September 5, 2006 as Disaboo, Inc., with the name changed to Disaboom, Inc. on November 12, 2006 and Cantor Group, Inc. on August 12, 2015. The Company was redomiciled to Wyoming on December 28, 2015 and changed its name to MedX Holdings, Inc. on the same day.

On December 19, 2019, there was a change of control of the Company, whereby Mark Miller resigned as director and CEO and Jason Black became the controlling shareholder and interim President through the assignment of a convertible loan note for \$70,000 to Mark Miller, the issuance of 50,000 series C preferred shares and the cancellation of 93,117,200 shares of common stock.

On December 21, 2019, Jeremy Amsden was appointed as the Company's CEO.

On February 24, 2020, the Company completed the acquisition of Bio Hydro LLC as a wholly owned subsidiary, through the issuance of 4,000,000 series B preferred shares. Simultaneous with the transfer, the Company completed the divestment of its subsidiaries, MJ Builders of MN and DDG Properties. Bio Hydro LLC is engaged in the development of real estate in Arizona to procure pharmaceutical grade water wells in Arizona's saturated zone, Maricopa County.

On June 5, 2020, Jeremy Amsden resigned as the Company's CEO and as a director due to an injury and was replaced by Hans Enriquez.

At no point in its history has the Company been classified as a shell by any governmental agency.

**NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation**

The accompanying pro forma financial statements have been prepared for MedX Holdings, Inc. in accordance with accounting principles generally accepted in the United States of America (US GAAP).

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of the financial statements have been included. The financial statements include acquired subsidiaries, as discussed below, and include all consolidation entries required to include those subsidiaries.

**Use of Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Cash and Cash Equivalents**

For the Balance Sheet and Statement of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. The Company had no cash equivalents as of December 31, 2019 or December 31, 2020.

## **Income Taxes**

Income taxes are provided in accordance with the FASB Accounting Standards (ASC 740), Accounting for Income Tax. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carry forwards. Any deferred tax expense (benefit) resulting from the net change during the year is shown as deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it was more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

## **Basic and Diluted Net Income (Loss) Per Share**

Net income (loss) per unit is calculated in accordance with Codification topic 260, "Earnings per Share" for the periods presented. Basic net loss per share is computed using the weighted average number of common membership units outstanding. Diluted loss per share has not been presented because the shares of common stock equivalents have not been included in the per share calculations as such inclusion would be anti-dilutive. Diluted earnings per share is based on the assumption that all dilutive stock options, warrants and convertible debt are converted or exercised applying the treasury stock method. Under this method, options, warrants and convertible debt are assumed exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase shares of common stock at the average market price during the period. Options, warrants and/or convertible debt will have a dilutive effect during periods of net profit only when the average market price of the units during the period exceeds the exercise or conversion price of the items.

## **Stock Based Compensation**

Codification topic 718 "Stock Compensation" requires that the cost resulting from all share-based transactions be recorded in the financial statements and establishes fair value as the measurement objective for share-based payment transactions with employees and acquired goods or services from non-employees. The codification also provides guidance on valuing and expensing these awards, as well as disclosure requirements of these equity arrangements. The Company adopted the codification upon creation of the Company and will expense share-based costs in the period incurred. The Company has not yet adopted a stock option plan and all share-based transactions and share based compensation has been expensed in accordance with the codification guidance.

## **Convertible Instruments**

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for "Accounting for Derivative Instruments and Hedging Activities". Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as "The Meaning of Conventional Convertible Debt Instrument".

The Company accounts for convertible instruments when it has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with professional standards when "Accounting for Convertible Securities with Beneficial Conversion Features," as those professional standards pertain to "Certain Convertible Instruments." Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying shares of common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares of common stock based upon the differences between the fair value of the underlying shares at the commitment date of the note transaction and the effective conversion price embedded in the note.

ASC 815-40 provides that, among other things, generally, if an event not within the entity's control could require net cash settlement, then the contract shall be classified as an asset or a liability.

## **Fair Value of Financial Instruments**

We adopted the guidance of ASC-820 for fair value instruments, which clarifies the definition of fair value, prescribes methods for determining fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value, as follows:

Level 1	Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
Level 2	Inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
Level 3	Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts for cash, accounts receivable, accounts payable and accrued expenses, and loans payable approximate their fair value based on the short-term maturity of these instruments. We did not identify any assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with the accounting guidance.

ASC 825-10 "Financial Instruments" allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. We did not elect to apply the fair value option to any outstanding instruments.

#### **Derivative Liabilities**

Derivative financial instruments consist of convertible instruments and rights to shares of the Company's common stock. The Company assessed that it had no derivative financial instruments as of December 31, 2020 and December 31, 2019.

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional. as described.

#### **Impact of New Accounting Standards**

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position, or cash flow.

#### **NOTE 3. GOING CONCERN**

The Company's financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. Currently, the Company does not have significant cash or other material assets, nor does it have operations or a source of revenue sufficient to cover its operation costs and allow it to continue as a going concern.

The Company has a limited operating history and had a cumulative net loss from inception to December 31, 2020 of \$2,201,361. The Company has a working capital deficit of \$866,178 as at December 31, 2020.

These financial statements for the year ending December 31, 2020 have been prepared assuming the Company will continue as a going concern, which is dependent upon the Company's ability to generate future profits and/or obtain necessary financing to meet its obligations as they come due.

The management has committed to an aggressive growth plan for the Company. The Company's future operations are dependent upon external funding and its ability to execute its business plan, realize sales and control expenses. Management believes that sufficient funding will be available from additional borrowings and private placements to meet its business objectives including anticipated cash needs for working capital, for a reasonable period of time. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business operation, or if obtained, upon terms favorable to the Company.

#### NOTE 4. ACQUISITIONS AND DISPOSALS

On January 15, 2018, the Company acquired MJ Builders of MN, LLC ("MJ") and DDG Properties LLC ("DDG") as wholly-owned subsidiaries. MJ serves as a licensed contractor in the state of Minnesota. In addition to building custom homes, MJ also owns several rental properties, as does DDG, both residential and commercial, all of which were leased at the point of acquisition, creating both a hard asset and ongoing revenue stream for the Company's shareholders. The CEO of MJ also became the CEO, President and controlling shareholder of the Company on completion of the acquisition.

The purchase price for MJ and DDG was \$1,000,000, satisfied through the issuance of 4,000,000 shares of series B Preferred Stock valued at \$0.25 per share, with the acquisition price broken down as follows:

Subsidiary	Allocation
Cash on hand	\$ -
Current assets	-
Fixed assets	411,311
Current liabilities	(411,311)
Goodwill	1,000,000
<b>Total</b>	<b>\$ 1,000,000</b>

The assets and liabilities acquired totaled nil, with the balance of the purchase price of \$1,000,000 allocated to Goodwill.

In October 2019, the Company sold all rental properties owned by MJ and DDG and repaid all loans related to these properties. The Goodwill related to the original acquisitions was written off as part of the transaction.

On February 24, 2020, the Company disposed of both MJ and DDG in full. The 4,000,000 series B Preferred Stock, valued at \$0.25 per share, that were issued for the acquisition, were returned to the Company.

Also on February 24, 2020, the Company acquired Bio Hydro LLC for \$1,000,000, satisfied through the issuance of 4,000,000 shares of series B Preferred Stock valued at \$0.25 per share.

#### NOTE 5. OTHER CURRENT ASSETS

Other current assets as at December 31, 2020 and December 31, 2019 are as follows:

	December 31, 2020	December 31, 2019
Prepaid expenses	-	-
<b>Totals</b>	<b>\$ -</b>	<b>\$ -</b>

#### NOTE 6. FIXED ASSETS

Through the acquisition of MJ Builders of MN, LLC ('MJ') and DDG Properties, LLC ('DDG'), the Company holds fixed assets with values at December 31, 2020 and December 31, 2019 as follows:

<b>Asset</b>	<b>Useful Life (years)</b>	<b>December 31, 2020</b>	<b>December 31, 2019</b>
Equipment	5	\$ 37,500	\$ 37,500
Accumulated depreciation		(22,500)	(15,000)
<b>Total</b>		<b>\$ 15,000</b>	<b>\$ 22,500</b>

During the year ending December 31, 2020, a total of \$7,500 was charged to the Statement of Operations for depreciation.

#### **NOTE 7. INTANGIBLE ASSETS**

The Company acquired MJ Properties of MN, LLC and DDG Properties, LLC in January 2018, creating \$1,000,000 of Goodwill through these transactions. The Company also capitalized its reorganization costs connected with these transactions.

On the sale of all of the Company's rental properties in October 2019, the Company extinguished the Goodwill created through the original transaction, as well as the capitalized reorganization costs.

On February 24, 2020, the Company acquired Bio Hydro LLC for \$1,000,000 in total, with \$996,000 of this represented by Goodwill.

<b>Asset</b>	<b>Description</b>	<b>December 31, 2020</b>	<b>December 31, 2019</b>
Goodwill	Goodwill	\$ 996,000	\$ -
Intangible assets	Design costs	200	200
<b>Totals</b>		<b>\$ 996,200</b>	<b>\$ 200</b>

Goodwill is not amortized, but is tested on an annual basis for impairment and the value of the goodwill written down accordingly if the value is below the carrying value in the financial statements.

There was no impairment test carried out during the period ending December 31, 2020.

#### **NOTE 8. LOANS AND NOTES PAYABLE**

The Company had multiple notes and loans payable as at December 31, 2020 and December 31, 2019, totaling \$96,242 and \$89,177 respectively, as follows:

<b>Description</b>	<b>Date of Loan Note</b>	<b>December 31, 2020</b>	<b>December 31, 2019</b>
12 month convertible loan note entered into with Northwoods Elite LLC; interest rate 20%; conversion price \$0.0001.	10/21/2019	\$ 21,242	\$ 19,220
12 month convertible loan note with M. Miller for change of control; interest rate 7.5%; convertible at \$0.001 per share; capped at \$75,000; preferred stock series C also issued	12/19/2019	75,000	69,957
<b>Total</b>		<b>\$ 96,242</b>	<b>\$ 89,177</b>
<b>Long-term total</b>		<b>\$ -</b>	<b>\$ -</b>
<b>Short-term total</b>		<b>\$ 96,242</b>	<b>\$ 89,177</b>

<b>Loans and Notes Amortization</b>	<b>Amount Due</b>
Due within 12 months	\$ 96,242
Due within 24 months	-
Due within 36 months	-
Due within 48 months	-
Due after 48 months	-
<b>Total</b>	<b>\$ 96,242</b>

#### **NOTE 9. DERIVATIVE LIABILITY**

The Company applies the provisions of ASC Topic 815-40, Contracts in Entity's Own Equity ("ASC Topic 815-40"), under which convertible instruments, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, embedded conversion options in convertible debt are recorded as a liability and are revalued at fair value at each reporting date. If the fair value of the note exceeds the face value of the related debt, the excess is recorded as change in fair value in operations on the issuance date.

The Company identified embedded derivatives related to the Convertible Promissory Notes issued in October and December 2019 for a total of \$88,500, with these embedded derivatives including certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivatives as of the inception date of the Convertible Promissory Notes and to adjust the fair value as of each subsequent balance sheet date. At the inception of the Convertible Promissory Notes, the Company determined a fair value for the embedded derivative using the Black Scholes Model based on the following assumptions:

Dividend yield	0.00%
Volatility	66.07-71.26%
Risk-free rate	1.60-1.74%

The initial fair value of the embedded debt derivative was \$546,665. This amount was allocated as a debt discount up to the proceeds of the notes of \$88,500, to be amortized over the life of the Convertible Loan Notes. The remaining balance of \$458,165 was charged to operations as a loss on change in fair value of the derivative liability.

The fair value of the embedded debt derivative was reviewed at December 31, 2019, using the following inputs:

Dividend yield	0.00%
Volatility	65.93%
Risk-free rate	1.68%

The fair value of the embedded debt derivative at December 31, 2019 was \$579,573, an increase in the valuation of the embedded debt derivative of \$32,908 for the period.

The following table provides a summary of changes in fair value of the Company's Level 3 derivative liabilities for the year ended December 31, 2019:

	December 31, 2019	December 31, 2018
Balance, beginning of period	\$ -	\$ -
Additions	546,665	-
Mark-to-market at modification date	32,908	-
Reclassified to additional paid-in capital upon modification of term	-	-
Balance, December 31, 2019	\$ 579,573	\$ -
Net loss due to change in fair value for the year, included in statement of operations	\$ (32,908)	\$ -

This mark-to-market change of \$32,908 for the period was charged to the statement of operations.

The Company identified embedded derivatives related to the Convertible Promissory Note issued in January 2020, for \$7,000, with these embedded derivatives including certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivatives as of the inception date of the Convertible Promissory Notes and to adjust the fair value as of each subsequent balance sheet date. At the inception of the Convertible Promissory Notes, the Company determined a fair value for the embedded derivative using the Black Scholes Model based on the following assumptions:

Dividend yield	0.00%
Volatility	66.11%
Risk-free rate	1.67%

The initial fair value of the embedded debt derivative was \$36,921. This amount was allocated as a debt discount up to the proceeds of the notes of \$7,000, to be amortized over the life of the Convertible Loan Notes. The remaining balance of \$29,921 was charged to operations as a loss on change in fair value of the derivative liability.

The fair value of the embedded debt derivative was reviewed at December 31, 2020, using the following inputs:

Dividend yield	0.00%
Volatility	70.82%
Risk-free rate	0.93%

The fair value of the embedded debt derivative at December 31, 2020 was \$769,936, an increase in the valuation of the embedded debt derivative of \$153,442 for the period.

The following table provides a summary of changes in fair value of the Company's Level 3 derivative liabilities for the year ending December 31, 2020:

	December 31, 2020	December 31, 2019
Balance, beginning of period	\$ 579,573	\$ -
Additions	36,921	546,665
Mark-to-market at modification date	153,442	32,908
Reclassified to additional paid-in capital upon modification of term	-	-
Balance, December 31, 2020	\$ 769,936	\$ 579,573
Net loss due to change in fair value for the year, included in statement of operations	\$ (153,442)	\$ (32,908)

This mark-to-market loss of \$153,442 for the period was charged to the statement of operations, along with the charge of \$36,921 from the convertible loan booked earlier in the year, for a total of \$190,363.

## NOTE 10. CAPITAL STOCK

The Company is a C Corp with shares of preferred stock and common stock authorized and issued.

### Preferred Stock

At December 31, 2020 the Company had authorized preferred stock in three designations totaling 100,000,000, as follows:

Preferred Stock Series A	<p>The Company is authorized to issue 50,000,000 shares of Series A, with a par value of \$0.001 per share and convertible into shares of common stock at a rate of 150 shares of common stock to one share of preferred stock series A. As at January 1, 2019, the Company had 2,900,000 shares of Series A preferred stock issued and outstanding.</p> <p>On November 14, 2019, the Company issued 2,500,000 shares of Series A preferred stock in return for services, taking the total number of shares outstanding to 2,900,000.</p>
Preferred Stock Series B	<p>The Company is authorized to issue 40,000,000 shares of Series B, with a par value of \$0.001 per share. As at January 1, 2019, the Company had no shares of Series B preferred stock issued and outstanding.</p>



On January 15, 2018, the Company issued 4,000,000 shares of Series B preferred stock at \$0.25 each as part of a transaction to acquire MJ Builders of MN, LLC and DDG Properties, LLC. This took the total number of shares of Series B preferred stock outstanding to 4,000,000.

On February 25, 2020, the Company canceled 4,000,000 shares of Series B preferred stock, valued at \$0.25 when they were returned as part of the disposal of MJ Builders of MN, LLC.

On February 25, 2020, the Company issued 4,000,000 shares of Series B preferred stock at \$0.25 each as part of a transaction to acquire Bio Hydro, LLC. This took the total number of shares of Series B preferred stock outstanding to 4,000,000.

#### Preferred Stock Series C

The Company is authorized to issue shares of Series C, with a par value of \$0.01 per share. As at January 1, 2019, the Company had no shares of Series C preferred stock issued or outstanding.

On December 19, 2019, the Company issued 50,000 shares of Series C preferred stock at \$0.01 each as part of a transaction whereby Jason Black acquired control of the Company. This took the total number of shares of Series C preferred stock outstanding to 50,000.

As at December 31, 2020, the Company had a total of 6,950,000 shares of preferred stock issued and outstanding.

#### Common Stock

At December 31, 2020, the Company is authorized to issue 1,000,000,000 shares of common stock with \$0.001 par value, increased from 200,000,000 on September 2, 2019.

As at January 1, 2018 the Company had 112,611,216 shares of common stock issued and outstanding, and has since made the following issuances:

On April 19, 2018, the Company issued 10,000,000 shares of common stock to PAG Group, LLC on conversion of an outstanding loan note for \$3,000, or \$0.0003 per share.

On December 4, 2018, the Company issued 11,000,000 shares of common stock to PAG Group, LLC on conversion of an outstanding loan note for \$3,300, or \$0.0003 per share.

On June 2, 2019, the Company issued 13,300,000 shares of common stock to Saeid Jaberian on conversion of an outstanding loan note for \$2,660, or \$0.0002 per share.

On October 1, 2019, the Company cancelled 295,000 shares of common stock owned by Mark Miller.

On December 11, 2019, the Company cancelled 93,117,200 shares owned by Mark Miller.

On June 29, 2020, the Company issued 5,000,000 shares of common stock in part settlement of an outstanding debt.

On July 1, 2020, the Company issued 60,000,000 shares of common stock in payment of consulting fees.

On July 27, 2020, the Company issued 5,000,000 shares of common stock in full settlement of an outstanding debt.

On November 29, 2020, the Company issued 10,000,000 shares of common stock in settlement of a \$1,000 of outstanding debt.

On December 17, 2020, the Company issued 10,000,000 shares of common stock in settlement of a \$1,000 of outstanding debt.

As of December 31, 2020, the Company had 143,499,016 shares of Common Stock issued and outstanding.

#### NOTE 10. STOCK OPTIONS AND WARRANTS

The Company does not have any stock options or warrants outstanding.

**NOTE 11. INCOME TAXES**

The Company uses the assets and liability method of accounting for income taxes pursuant to SFAS No. 109 "Accounting for Income Taxes". Under the assets and liability method of SFAS No. 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

In June 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes." Specifically, the pronouncement prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken from year ended December 31, 2015 tax return onwards. The interpretation also provides guidance on the related derecognition, classification, interest and penalties, accounting for interim periods, disclosure and transition of uncertain tax positions. The Company adopted this interpretation effective on inception.

The Company has made losses since inception and has a carry forward tax loss balance. The Company believes that no income tax is due to be paid by either the parent company or any of its subsidiaries as at the date of these financial statements.

**NOTE 12. COMMITMENTS AND CONTINGENCIES**

The Company believes that it has no commitments or contingencies to be disclosed as at December 31, 2020.

**NOTE 13. SUBSEQUENT EVENTS**

On January 12, 2021 Jason Black and Hans Enriquez completed a stock purchase agreement whereby Jason Black transferred the Series C Preferred control block to Hans Enriquez in consideration of a 2 year lease hold on 3 acres of land on a licensed hemp farm in Laredo Texas.

The Company intends to change its focus away from developing pharmaceutical grade water assets in Arizona and focus on developing assets, owned by CEO, Hans Enriquez, within the hemp farming and CBD industries in Texas.